News / Blog
May Holidays 2023 - Pay Attention!
Excegran tablets for epilepsy seizures from Japan
Product Code :
Availability : 6
General information about Japanese Excegran tablets for epilepsy seizures
Package: 100 tablets
Manufacturer: Sumitomo Dainippon Pharma, Japan
Active ingredient: zonisamide 100 mg
Medical effect: Excegran tablets are effective for controlling epilepsy seizures. They are suitable for the following diseases and conditions:
- temporal lobe epilepsy,
- focal impaired awareness (complex partial seizures),
- refractory seizures
- secondarily generalized seizures (bilateral tonic-clonic seizures),
- focal aware (simple partial seizures).
Contraindications and precautions:
Do not use in pregnant or breastfeeding women. Do not use in patients with liver diseases. If an allergic reaction occurs, stop using the product and consult with your doctor. If you are taking any other medicine, please consult with your doctor before use.
Dosage and Administration of Excegran tablets for epilepsy seizures from Japan
adults, take 1 or 2 tablets in 1 to 3 divided doses on the first day. Then, increase the dose every 1 to 2 weeks to 2 to 4 tablets in 1 to 3 divided doses a day.
children, take 2 to 4mgof active ingredient per kg of weight in 1 to 3 divided doses on the first day. Then, increase the dose every 1 to 2 weeks to 4 to 8 mg per kg in 1 to 3 divided doses a day.
The maximum dose is 6 tablets a day for adults, 12 mg per kg of the active ingredient a day for children. Do not exceed the maximum dose.
About the effects of Japanese Excegran tablets for epilepsy seizures
Excegran tablets for epilepsy seizures from Japan contain zonisamide, a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It works on central nervous system and helps to control epilepsy seizures. Researches show that zonisamide is long-term safe and effective for the treatment of partial, generalized and mixed seizures (G. Zaccara, L. M. Specchio. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatric Disease and Treatment, 2009; 5: 249–259).